Advances in the understanding of the functions of individual opioid receptor subtypes and the development of selective opioid ligands, including DOR selective agonists, and KOR and NOP receptor selective antagonists, has brought promise for the potential of opioidergic agents as viable treatment options for MDD, without the risk of addiction. Here, OPRD1 is linked to major depressive disorder.